iMD Companies, Inc. (OTC: ICBU) announced it has entered advanced due diligence on two potential acquisition targets, one in the cryptocurrency infrastructure sector and the other in the medical technology space. The company, based in Rancho Cordova, CA, stated that both opportunities align with its strategic focus on high-growth industries supported by scalable technologies and long-term market demand.
According to the press release, iMD believes these potential acquisitions could strengthen its position across emerging sectors and support future revenue expansion. The company's CEO, Richard Wilson, emphasized a disciplined approach. "We are encouraged by the progress we've made in evaluating these opportunities," Wilson said. "Our approach remains disciplined and focused on identifying assets that can deliver sustainable growth and long-term value for our shareholders."
The due diligence process is ongoing, with completion anticipated in the coming weeks. iMD Companies plans to provide updates as evaluations progress. The company stated it remains committed to maintaining transparency with shareholders and will communicate material developments in a timely manner.
This move comes as iMD Companies, a Florida corporation focused on acquisitions and technology in cryptocurrency, blockchain, and application development, seeks to expand its portfolio. The company's stock trades on the OTC Markets under the ticker ICBU. For more information, visit imdcompaniesinc.com or follow @imd_inc on X for real-time updates.
The announcement highlights iMD's continued interest in the cryptocurrency sector, which has seen significant volatility and regulatory scrutiny. By targeting both crypto infrastructure and medical technology, the company is diversifying its potential revenue streams. Medical technology, in particular, represents a stable industry with consistent demand, while cryptocurrency infrastructure could offer high growth if market conditions improve.
Investors will be watching for further details on the targets and the terms of any potential deals. The company has not disclosed the names of the acquisition targets or the financial terms involved. As with any forward-looking statements, iMD cautioned that actual results may differ materially from expectations due to various risks and uncertainties.
